Licogi 13 JSC (HNX:LIG)
Vietnam · Delayed Price · Currency is VND 4,100.00
-100.00 (-2.38%)
At close: Aug 5, 2025
Verve Therapeutics Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 |
| 4,339,226 | 3,695,152 | 3,321,343 | 1,405,590 | 847,818 | |
Revenue Growth (YoY) | 10.29% | 11.25% | 136.30% | 65.79% | - |
Cost of Revenue | 4,198,547 | 3,579,441 | 3,239,525 | 1,305,680 | 761,841 |
Gross Profit | 140,679 | 115,711 | 81,818 | 99,910 | 85,977 |
Selling, General & Admin | 75,011 | 72,631 | 101,917 | 37,150 | 29,038 |
Operating Expenses | 75,011 | 72,631 | 101,917 | 37,150 | 29,038 |
Operating Income | 65,667 | 43,080 | -20,099 | 62,760 | 56,939 |
Interest Expense | -45,727 | -51,951 | -130,357 | -43,602 | -49,838 |
Interest & Investment Income | 9,638 | 9,638 | 25,648 | 6,352 | 1,583 |
Earnings From Equity Investments | 5,592 | 6,342 | - | 52.56 | 28.29 |
Other Non Operating Income (Expenses) | -22,769 | -1,540 | 134,116 | 7.84 | -5,777 |
EBT Excluding Unusual Items | 12,402 | 5,569 | 9,308 | 25,570 | 2,936 |
Gain (Loss) on Sale of Investments | 8,519 | 8,519 | - | - | - |
Gain (Loss) on Sale of Assets | 1,056 | 1,056 | -1,621 | - | - |
Other Unusual Items | -3,910 | -3,910 | -4,836 | - | - |
Pretax Income | 18,067 | 11,234 | 2,851 | 25,570 | 2,936 |
Income Tax Expense | 6,665 | 5,179 | 5,049 | 7,218 | 2,416 |
Earnings From Continuing Operations | 11,401 | 6,055 | -2,198 | 18,352 | 520.46 |
Minority Interest in Earnings | -6,571 | -3,966 | 312.69 | -2,777 | 329.56 |
Net Income | 4,831 | 2,089 | -1,885 | 15,576 | 850.02 |
Preferred Dividends & Other Adjustments | - | - | 777.51 | - | - |
Net Income to Common | 4,831 | 2,089 | -2,663 | 15,576 | 850.02 |
Net Income Growth | - | - | - | 1732.38% | - |
Shares Outstanding (Basic) | 95 | 94 | 94 | 15 | 15 |
Shares Outstanding (Diluted) | 95 | 94 | 94 | 15 | 15 |
Shares Change (YoY) | 3.19% | - | 539.68% | -0.46% | - |
EPS (Basic) | 50.92 | 22.17 | -28.26 | 1057.45 | 57.45 |
EPS (Diluted) | 50.92 | 22.17 | -28.26 | 1057.45 | 57.45 |
EPS Growth | - | - | - | 1740.79% | - |
Free Cash Flow | -85,313 | 91,475 | -430,398 | 758,795 | 546,027 |
Free Cash Flow Per Share | -899.32 | 970.85 | -4567.98 | 51515.53 | 36901.05 |
Gross Margin | 3.24% | 3.13% | 2.46% | 7.11% | 10.14% |
Operating Margin | 1.51% | 1.17% | -0.60% | 4.46% | 6.72% |
Profit Margin | 0.11% | 0.06% | -0.08% | 1.11% | 0.10% |
Free Cash Flow Margin | -1.97% | 2.48% | -12.96% | 53.98% | 64.40% |
EBITDA | 85,261 | 73,888 | 39,346 | - | - |
EBITDA Margin | 1.97% | 2.00% | 1.19% | - | - |
D&A For EBITDA | 19,594 | 30,808 | 59,444 | - | - |
EBIT | 65,667 | 43,080 | -20,099 | 62,760 | 56,939 |
EBIT Margin | 1.51% | 1.17% | -0.60% | 4.46% | 6.72% |
Effective Tax Rate | 36.89% | 46.10% | 177.08% | 28.23% | 82.27% |
Revenue as Reported | 4,339,226 | 3,695,152 | 3,321,343 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.